Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 2/2010

01-06-2010 | Letter to the Editor

Renal safety and osteonecrosis of the jaw in cancer patients receiving intravenous bisphosphonates

Authors: Sercan Aksoy, Omer Dizdar, Kadri Altundag

Published in: Medical Oncology | Issue 2/2010

Login to get access

Excerpt

To the Editor, …
Literature
1.
Bonomi M, Nortilli R, Molino A, Sava T, Santo A, Caldara A, et al.. Renal toxicity and osteonecrosis of the jaw in cancer patients treated with bisphosphonates: a long-term retrospective analysis. Med Oncol. 2009 Mar 28 [Epub ahead of print].
2.
Dincer M, Altundag K, Harputluoglu H, Aksoy S, Cengiz M, Gullu I. Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases. Med Oncol. 2008;25:356–9. doi:10.​1007/​s12032-008-9045-3.CrossRefPubMed
3.
Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008;23:826–36. doi:10.​1359/​jbmr.​080205.CrossRefPubMed
Metadata
Title
Renal safety and osteonecrosis of the jaw in cancer patients receiving intravenous bisphosphonates
Authors
Sercan Aksoy
Omer Dizdar
Kadri Altundag
Publication date
01-06-2010
Publisher
Springer US
Published in
Medical Oncology / Issue 2/2010
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-009-9236-6

Other articles of this Issue 2/2010

Medical Oncology 2/2010 Go to the issue

Original Paper

TNF-α and its inhibitors in cancer

Original Paper

Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer

Original Paper

Diffuse large B-cell lymphoma: experience from a tertiary care center in north India

Original Paper

T-cell large granular lymphocytic (T-LGL) leukemia: a single institution experience

Original Paper

Prognostic factors in patients with small cell lung carcinoma

Original Paper

Mean platelet volume increase after tamoxifen, but not after anastrazole in adjuvant therapy of breast cancer

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits